Revelation Biosciences Files 8-K on Security Holder Rights

TL;DR

REV B is filing an 8-K on Dec 3rd about security holder rights and votes - check it out.

AI Summary

Revelation Biosciences, Inc. filed an 8-K on December 3, 2025, reporting material modifications to security holder rights and submitting matters to a vote. The filing also includes other events and financial statements/exhibits. The company was formerly known as Petra Acquisition Inc. until April 23, 2020.

Why It Matters

This 8-K filing indicates significant corporate actions and potential changes affecting Revelation Biosciences' security holders, requiring their attention and possible participation in votes.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can impact stock price, and this one specifically mentions modifications to security holder rights and votes.

Key Numbers

• 20251203 — Filing Date (Date of the 8-K filing)

Key Players & Entities

• REVELATION BIOSCIENCES, INC. (company) — Registrant
• Petra Acquisition Inc. (company) — Former company name
• December 03, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-39603 (commission_file_number) — SEC file number
• 84-3898466 (ein) — IRS Employer Identification Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
• $579,600 — of common stock at an exercise price of $579,600 per share REVBW The Nasdaq Stock Ma

Filing Documents

• revb-20251203.htm (8-K) — 64KB
• revb-ex99_1.htm (EX-99.1) — 7KB
• 0001193125-25-306915.txt ( ) — 215KB
• revb-20251203.xsd (EX-101.SCH) — 47KB
• revb-20251203_htm.xml (XML) — 7KB

03 Material Modification to Rights of Security Holders

Item 3.03 Material Modification to Rights of Security Holders. Pursuant to the terms of the Class I Common Stock Warrants, the expiration date of such Warrants is five years from the date of stockholder approval of the reservation of shares to the extent that issuances under the Warrants may exceed 20% of the Company's total outstanding shares, which could trigger the Exchange Cap, as described below. By virtue of the stockholder approval on December 3, 2025, the expiration date of such Warrants is now fixed at December 3, 2030.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the Special Meeting of the Company, a total of 2,460,527 shares of the Company's common stock, being greater than one-third of the 5,924,137 shares of common stock issued and outstanding and entitled to vote as of the record date for the Special Meeting, were present virtually, or represented by valid proxy at the Special Meeting, constituting a quorum. The following proposals, each as described further in the definitive proxy statement filed with the Securities and Exchange Commission on November 10, 2025, were voted upon by the stockholders: Proposal 1 – Authorization to issue common stock in connection with Warrants Stockholders approved the reservation and issuance of shares of our common stock pursuant to the Class I Common Stock Warrants, dated September 11, 2025, entered into between us and certain purchasers in connection with a warrant inducement letter dated September 10, 2025, to the extent that issuances under the Warrants may exceed 20% of the Company's total outstanding shares, which could trigger the Exchange Cap, based on the votes listed below: For Against Abstain 2,347,650 109,808 3,069 There were no broker non-votes regarding the election of directors. Proposal 2 – Discretionary Authority to adjourn the Special Meeting Stockholders approved of the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the issuance of shares in excess of the Exchange Cap, based on the votes listed below: For Against Abstain 2,377,129 82,853 545 There were no broker non-votes regarding this proposal.

01 Other Information

Item 8.01 Other Information. At the conclusion of the meeting, James Rolke, the Company's CEO, provided a brief corporate update regarding recent progress and product developments. A copy of the transcript of the corporate update is furnished as Exhibit 99.1 to this Current Report on Form 8K and is incorporated herein by reference. The information in this Item 8.01 and in Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Transcript of Corporate Update 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: December 3, 2025 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

View Full Filing

View this 8-K filing on SEC EDGAR